FDA Cancels Merck's Sugammadex NDA Advisory Panel Meeting

Source: Nasdaq

Mar 18, 2015

Nasdaq

Merck received news that the FDA cancelled a previously scheduled meeting with the Anesthetic and Analgesic Drug Products Advisory Committee, intended to consider Merck's resubmitted new drug application (NDA) for sugammadex.

Merck is looking to get sugammadex approved in the U.S. for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.

The FDA informed Merck that it intends to conduct additional site inspections related to a hypersensitivity study of the drug.

Read the Nasdaq article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments